Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2013 May;42(4):557-77.
doi: 10.1097/MPA.0b013e31828e34a4.

Consensus guidelines for the management and treatment of neuroendocrine tumors

Pamela L Kunz  1 , Diane Reidy-Lagunes, Lowell B Anthony, Erin M Bertino, Kari Brendtro, Jennifer A Chan, Herbert Chen, Robert T Jensen, Michelle Kang Kim, David S Klimstra, Matthew H Kulke, Eric H Liu, David C Metz, Alexandria T Phan, Rebecca S Sippel, Jonathan R Strosberg, James C Yao; North American Neuroendocrine Tumor Society
Affiliations
Practice Guideline

Consensus guidelines for the management and treatment of neuroendocrine tumors

Pamela L Kunz et al. Pancreas. 2013 May.

Abstract

Neuroendocrine tumors are a heterogeneous group of tumors originating in various anatomic locations. The management of this disease poses a significant challenge because of the heterogeneous clinical presentations and varying degrees of aggressiveness. The recent completion of several phase 3 trials, including those evaluating octreotide, sunitinib, and everolimus, demonstrate that rigorous evaluation of novel agents in this disease is possible and can lead to practice-changing outcomes. Nevertheless, there are many aspects to the treatment of neuroendocrine tumors that remain unclear and controversial. The North American Neuroendocrine Tumor Society published a set of consensus guidelines in 2010, which provided an overview for the treatment of patients with these malignancies. Here, we present a set of consensus tables intended to complement these guidelines and serve as a quick, accessible reference for the practicing physician.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest and Source of Funding: Pamela L. Kunz receives grant funding from Genentech, Merck, and Sanofi, is a consultant for OncoMed and Guardant Health, and has stock options from Guardant Health. Diane Reidy-Lagunes receives grant funding from Novartis and Merck, is a consultant for Novartis and Pfizer, and receives honorarium from Novartis. Jennifer A. Chan receives grant funding from Novartis, Onyx/Bayer, and Merck and has stock options from Merck. Eric H. Liu is a consultant for Novartis. Lowell B. Anthony receives grant funding from Novartis. David C. Metz is a consultant for Novartis and receives grant funding from Ipsen. Alexandria T. Phan is a consultant for Ipsen. Jonathan R. Strosberg is a consultant for Novartis and Pfizer, receives grant funding from Genentech and Novartis, and receives honorarium from Genentech, Pfizer and Sanofi. Matthew H. Kulke is a consultant for Novartis, Ipsen, Pfizer and Lexicon and receives grant funding from Novartis. James C. Yao serves as a consultant for Novartis, Ipsen and Pfizer, and receives grant funding from Novartis. For the remaining authors no disclosures were declared.

References

    1. Anthony LB, Strosberg JR, Klimstra DS, et al. The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (nets): well-differentiated nets of the distal colon and rectum. Pancreas. 2010 Aug;39(6):767–774. - PubMed
    1. Boudreaux JP, Klimstra DS, Hassan MM, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas. 2010 Aug;39(6):753–766. - PubMed
    1. Chen H, Sippel RS, O'Dorisio MS, Vinik AI, Lloyd RV, Pacak K. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010 Aug;39(6):775–783. - PMC - PubMed
    1. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010 Aug;39(6):707–712. - PubMed
    1. Kulke MH, Anthony LB, Bushnell DL, et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas. 2010 Aug;39(6):735–752. - PMC - PubMed

Publication types

Substances